FORM 10-K For the fiscal year ended December 31, 2023 For the transition period from _________ to ________ (Exact name of registrant as specified in its charter) 02453 (ZipCode) Title of each class Trading Symbol Name of each exchange on which registered Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by th ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | Nevada | 001-38543 | 26-1265381 | | --- | --- | --- | | (State or other jurisdiction | (Commission File Number) | (IRS Employer | | of incorporation) | | Identification No.) | ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 260 Charles Street, Suite 302, Waltham, MA 02453 (Address of principal executiv ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 260 Charles Street, Suite 302 Waltham, MA 02453 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the t ...

Financial Data and Key Metrics Changes - Q3 2023 revenue reached $16.3 million, an 8% increase from $15.1 million in Q3 2022, marking a record third quarter for the company [5][21] - Gross margin decreased slightly from 62.4% in Q3 2022 to 60% in Q3 2023, attributed to solution and channel partner mix [21] - Net loss for Q3 2023 was $2.9 million, or $0.17 per share, compared to a net loss of $3.5 million in the same period in 2022 [22] - Adjusted EBITDA for Q3 2023 was $9.9 million, effectively flat year-over-year [22] - Operating cash flow was positive at $1.5 million for the quarter, with cash and short-term investments totaling $63.5 million as of September 30, 2023 [23] Business Line Data and Key Metrics Changes - The company reported 16 total RWD deals for the year, exceeding the original expectation of approximately 10 deals, indicating strong client adoption [6] - Average revenue for the top 20 pharmaceutical manufacturers was $2.1 million, with a net revenue retention rate improving to 93% from 89% in Q2 2023 [26][27] - Medicx, acquired for $95 million, is expected to enhance the company's revenue streams, particularly in patient marketing [24][15] Market Data and Key Metrics Changes - The company is experiencing a normalization of macro headwinds that had previously impacted the industry, leading to improved client engagement and investment [8][44] - The acquisition of Medicx is anticipated to expand the company's omnichannel reach beyond HCPs to patients, enhancing marketing capabilities [14][15] Company Strategy and Development Direction - The company is focused on enhancing its Dynamic Audience Activation Platform (DAAP) to integrate AI capabilities, improving pharmaceutical marketing solutions [10][11] - The acquisition of Medicx is seen as a strategic move to unlock value for customers and expand market opportunities, with expectations of significant revenue growth [19][120] - The company aims to maintain a strong focus on the top 20 pharmaceutical manufacturers while also exploring opportunities in the broader market [111] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's momentum heading into 2024, citing a positive response from clients and a strong renewal rate [8][12] - The company anticipates revenue for 2023 to be between $68 million and $70 million, with preliminary guidance for 2024 set at a minimum of $110 million [6][25] - Management noted that the recent enhancements and acquisitions position the company well to address challenges faced by clients in the healthcare system [118][120] Other Important Information - The company has completed over half of its planned cost reductions, with full benefits expected to be realized in 2024 [19][72] - The Medicx acquisition is expected to be accretive to earnings, contributing to revenue growth and profitability [120] Q&A Session All Questions and Answers Question: Can you share expected revenue contribution from Medicx for 2024? - Management indicated it is too early to provide specific figures but expressed confidence in the integration and growth potential [31][35] Question: What is the average size of new deals? - The average deal size remains in the $1 million to $2 million range, with expectations for growth as the company scales its offerings [36][37] Question: What drove the better-than-expected results in Q3? - The outperformance was attributed to the successful implementation of DAAP and increased client engagement [41][42] Question: How are clients responding to the competitive landscape? - Clients are returning after experimenting with other vendors, primarily due to the company's proven ROI and effective measurement capabilities [53][54] Question: How does the Medicx acquisition impact decision-making at the brand level? - The decision-making process involves both HCP and patient marketing leads, with the company now positioned to engage both sides effectively [60][70] Question: What is the expected impact of cost-cutting measures in 2024? - Cost reductions are expected to be fully realized in 2024, contributing to improved adjusted EBITDA margins [72]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation | (Exact name of registrant as specified in its charter) | | | --- | --- | | Nevada | 26-1265381 | | (State or ...

Financial Data and Key Metrics Changes - The reported revenue for Q4 2022 was $19.7 million, a decrease of 3% from $20.3 million in the same period in 2021 [33] - The company expects a revenue increase of at least 10% year-over-year for the full year of 2023, with Q1 revenue guidance between $11.5 million and $13 million [13][49] - Gross margin for Q4 increased from 61% to 63%, with full-year 2023 gross margin guidance between 58% and 62% [8][33] Business Line Data and Key Metrics Changes - The average revenue for the top 20 pharmaceutical manufacturers declined nearly 14% year-over-year to $2.1 million due to extended deal closing timelines and higher turnover rates [13] - The net revenue retention rate declined to 90% due to macroeconomic factors impacting client programs [14] Market Data and Key Metrics Changes - The company reported a net loss of $325,000 in Q4 2022 compared to a net income of approximately $623,000 in Q4 2021 [10] - Cash flow from operations was $10.7 million for 2022, with $2.8 million generated in Q4 [11] Company Strategy and Development Direction - The company is following a land-and-expand strategy, focusing on delivering superior ROI, which remains above a 10:1 ratio [7] - The company aims to capture a greater portion of the available industry white space over the next three to five years, with total industry digital spend exceeding $10 billion [24][25] - The strategic positioning is expected to yield significant dividends over the next three to five years, with revenue projected to increase to multiples of current levels [31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the backlog being stronger than in previous years, indicating a potential for at least 10% growth [19][20] - The competitive landscape is crowded, but the company believes it has a unique data set and strong client response due to its integrated solutions [22][26] - Management acknowledged macroeconomic headwinds but noted positive trends since mid-2022, taking a conservative approach to guidance [49][52] Other Important Information - The company repurchased 1.2 million shares at an average price of $16.49, reducing total outstanding shares by nearly 7% [12] - Operating expenses increased to approximately $13.3 million in Q4 2022, primarily due to stock-based compensation and the EvinceMed acquisition [9][34] Q&A Session Summary Question: What is the revenue outlook for the year? - Management expects a drop in revenue of about 11% year-over-year in Q1 but anticipates 10% growth for the full year, with a stronger backlog [1][19] Question: How much of the growth is contracted versus needing to be won? - Typically, the company has 40% to 60% visibility for the rest of the year, which supports the 10% growth target [3] Question: What are the impacts of competition on specific products? - The competitive environment has increased, elongating the sales cycle, but the company believes its unique offerings will prevail [5][21] Question: What is the management's view on pharma's engagement with digital solutions? - There is a positive trend in pharma's engagement with digital solutions, with a focus on ROI and the need for effective communication with healthcare providers [39][42] Question: What are the expectations for the RWE pipeline? - The RWE pipeline contains several dozen deals, primarily from existing clients looking to upgrade, indicating a robust growth opportunity [69][70]

Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Chief Financi ...

Financial Data and Key Metrics Changes - Reported revenue for Q3 2022 was $15.1 million, a decrease of 6% from $16.1 million in Q3 2021, attributed to macro factors [17] - Gross margin increased from 56.3% in the previous year to 62.4% in Q3 2022 due to a favorable solution and network partner mix [17] - Operating expenses rose to approximately $13.2 million in Q3 2022 from about $9 million in the same period last year, primarily due to team expansion and the acquisition of EvinceMed [19] - GAAP net loss was $3.5 million in Q3 2022 compared to a net income of $0.04 million in Q3 2021; non-GAAP net income was approximately $1.3 million or $0.07 per share [20] - Cash, cash equivalents, and short-term investments totaled $78.8 million as of September 30, 2022, down from $87.4 million as of June 30, 2022, due to share buybacks [21] Business Line Data and Key Metrics Changes - The average revenue for top 20 pharmaceutical manufacturers decreased to $2.2 million at the end of Q3 2022 from $2.5 million in the previous year, influenced by delays in contract renewals [23] - Net revenue retention for Q3 2022 was 96%, a reduction compared to Q2 2022, driven by lower revenue growth [24] Market Data and Key Metrics Changes - The company is experiencing a shift in pharma manufacturers reallocating commercial spend towards omnichannel digital solutions, which is expected to capture a significant share of the market [10][15] - The company anticipates having at least six real-world evidence (RWE) deals running in the first half of 2023, which could contribute to over 20% top-line growth [11] Company Strategy and Development Direction - The company is focused on expanding its RWE solutions, which are seen as a significant growth driver aligned with digital trends in the life sciences industry [10][15] - The management emphasizes the importance of innovative partnerships and omni-channel strategies to enhance client relationships and improve gross margins [31] - The company aims to capture a larger market share as pharma spends shift from traditional methods to digital solutions, positioning itself for strong profitable growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism that macro headwinds will subside in 2023, with improvements in FDA drug approvals and employee turnover rates in the life sciences industry [6] - The company is confident in its ability to grow revenue and expand its partner network without needing additional capital for operating purposes [22] - Management highlighted the importance of maintaining a strong balance sheet and cash flow to support future growth opportunities [22] Other Important Information - The company has initiated a $20 million share repurchase program, having bought back 693,000 shares for $12.2 million at an average price of $17.66 [21] - The company continues to strengthen its channel network, recently renewing its exclusive partnership with NewCrop, enhancing its e-prescribing capabilities [14] Q&A Session Summary Question: Update on channel partners and gross margin - Management noted that channel partnerships are crucial, with a focus on innovative solutions that enhance client relationships and improve gross margins [31] Question: Confidence in Q4 guidance and seasonality - Management expressed a 95% confidence level in achieving the midpoint of the guidance, noting typical seasonal ramp-up in Q4 [33] Question: Details on RWE contracts and contributions to 2023 - Management confirmed that the new RWE contracts are multimillion-dollar deals, contributing positively to gross margins and revenue predictability [40] Question: Competitive landscape and market dynamics - Management indicated that smaller competitors are struggling to deliver on promises, leading to increased client interest in their solutions [42] Question: Retention rates and future expectations - Management believes retention rates are nearing the bottom and expects recovery as new contracts come online [53] Question: Revenue contribution from RWE and contract economics - Management clarified that RWE contracts can range from $0.5 million to $1.5 million in setup fees, transitioning to higher CPM distributions [60] Question: Guidance for Q4 and factors affecting it - Management attributed the wide guidance range to ongoing headwinds and the potential for client buy-ups [65]